使用 ERCC1 的 8092C/A 多态性预测上皮性卵巢癌铂类化疗的疗效：一项荟萃分析。
Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.
机构信息
Department of Molecular Biology .
出版信息
Biomarkers. 2014 Mar;19(2):128-34. doi: 10.3109/1354750X.2014.882414. Epub 2014 Feb 5.
BACKGROUND
In the present study, we performed this meta-analysis to estimate the association between excision repair cross-complementation group 1 (ERCC1) gene polymorphism and clinical resistance to platinum-based chemotherapy in the patients with epithelial ovarian cancer (EOC).
METHODS
A total of 10 studies consist of 1479 EOC patients relating ERCC1 rs11615C/T and rs3212986C/A polymorphisms to the response of platinum-based chemotherapy were included in this meta-analysis.
RESULTS
The analysis showed that the AA genotype of the rs3212986C/A polymorphism in ERCC1 was associated with progression-free survival of EOC patients (HR = 1.39, 95% CI = 1.12-1.73) and that the CA or AA genotypes could influence overall survival (HR = 1.28, 95% CI = 1.05-1.56; and HR = 1.55, 95% CI = 1.17∼2.05, respectively).
CONCLUSIONS
The ERCC1 rs3212986C/A polymorphism may be a useful prognostic marker in platinum-based treatment of EOC.
背景
在本研究中，我们进行了这项荟萃分析，以评估切除修复交叉互补组 1（ERCC1）基因多态性与上皮性卵巢癌（EOC）患者对铂类化疗的临床耐药性之间的关系。
方法
共有 10 项研究纳入了 1479 名 EOC 患者，这些研究涉及 ERCC1 rs11615C/T 和 rs3212986C/A 多态性与铂类化疗反应的关系。
结果
分析表明，ERCC1 中 rs3212986C/A 多态性的 AA 基因型与 EOC 患者的无进展生存期相关（HR=1.39，95%CI=1.12-1.73），CA 或 AA 基因型可能影响总生存期（HR=1.28，95%CI=1.05-1.56；和 HR=1.55，95%CI=1.17-2.05）。
结论
ERCC1 rs3212986C/A 多态性可能是 EOC 铂类治疗中有用的预后标志物。
Zotero 插件